Transient inhibition of MAPK signaling increased both AKT activity and the capacity for blastocyst formation.

(A) Timeline of U0126 treatment during early IVM (0–22 h). (B) Effect of U0126 treatment on the blastocyst formation rate under the indicated treatment condition. Representative photographs of blastocysts (left) and blastocyst development rate under the indicated treatment conditions (right). Bar = 50 μm. The data are from three independent experiments, and the values represent the means ± SEM (*P P P < 0.05). (E) Nuclear maturation rate of matured oocytes under the indicated treatment conditions. (F) Effects of U0126 treatment at the indicated doses on p-AKT levels. (G) Western blot of p-AKT and p-ERK using oocytes cultured under the indicated treatment conditions.